Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses

International Journal of Impotence Research

Volumn 14, Issue 5, 2002, Pages 397-405

  Mulhall, J P ^a,b   Anderson, M S ^a,b   Lubrano, T ^a   Shankey, T V ^a,b  

^a Hines VA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Aneusomy; Fibroblasts; P53; Peyronie's disease; Transformation

Indexed keywords

CELL CULTURE; CELL CYCLE; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOGENETICS; DISEASE MODEL; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MYOFIBROBLAST; PATHOPHYSIOLOGY; PENILE FIBROSIS; PEYRONIE DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUNICA ALBUGINEA;

BIOLOGICAL PRODUCTS; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; GENOTYPE; HUMANS; MALE; PENILE INDURATION; PENIS; PHENOTYPE;

EID: 0036804595     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900874     Document Type: Review

References (44)

1. Schwarzer U et al. Prevalence of Peyronie's disease: Results of an 8000 man survey. J Urol 2000; 163: 167.
2. Jordan G. Peyronie's disease. In: Walsh PC, ed. Campbell's urology. WB Saunders: Philadelphia, 1992, pp 2204-2222.
3. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990, 144: 1376-1382.
4. Devine CJJ, Somers RD, Lagoda LE. Peyronie's disease: Pathophysiology. Prog Clin Biol Res 1991; 370: 355-358.
5. Devine CJJ, Jordan GH, Somers RD. Peyronie's disease: Cause and surgical treatment. AUA Today 1989; 2: 1-7.
6. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the etiology of Peyronie's disease. Br J Urol 1982; 54: 748-751.
7. Weidner W, Schroeder-Printzen I, Weiske W, Vosshenrich R. Sexual dysfunction in Peyronie's disease: An analysis of 222 patients without previous local plaque therapy. J Urol 1997; 157: 325-328.
8. Alman RA et al. Aggressive fibromatosis. J Pediatr Orthop 1992; 12: 1-10.
9. Vande Berg JS, Devine CJ Jr, Horton CE. Mechanisms of calcification in Peyronie's disease. J Urol 1982; 127: 52-54.
10. Liang SB et al. Tetrasomy 12 in ovarian tumors of the comafibroma group: A fluorescence in situ hybridization analysis using paraffin sections. Pathol Int 2001; 51: 37-42.
11. Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF. The immunological features of Peyronie's disease. J Urol 1996; 155: 159-162.
12. Devine CJJ, Somers KD, Jordan GH, Scholssberg SM. Proposal: Trauma as the cause of Peyronie's lesion. J Urol 1997; 157: 285-290.
13. Leffell MS et al. Non-association of Peyronie's disease with HLA B7 cross-reactive antigens. J Urol 1982; 127: 1223-1224.
14. Nachsteim DA, Rearden A. Peyronie's disease is associated with an HLA class II antigen HLA-DQ5, implying an autoimmune etiology. J Urol 1996; 156: 1330.
15. El-Sakka AI et al. An animal model of Peyronie's-like condition associated with an increase of TGF beta mRNA and protein expression. J Urol 1997; 158: 2284-2290.
16. Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001; 165: 419-423.
17. Yamanaka M et al. Genetic instability in Peyronie's disease. J Urol 2001; 165: 201.
18. Pierpaoli S et al. Chromosomal instability in Peyronie's disease plaques: Preliminary data. J Urol 1998; 159: 362A.
19. Mulhall JP, Thom J, Lubrano T, Shankey TV. Cytogenetic evidence in support of Peyronie's disease being a tunical field defect process. J Urol 2000; 163: 747A.
20. Somers KD et al. Cell culture of Peyronie's disease plaque and normal penile tissue. J Urol 1982; 127: 585-588.
21. Smith BH. Peyronie's disease. Am J Clin Path 1966; 45: 670- 674.
22. Brock G et al. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 1997; 151: 276-281.
23. Devine CJJ, Angemeir RW. Anatomy of the penis and male perineum. AUA Update 1993; 12: 1-6.
24. El-Sakka AI et al. Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br J Urol 1998; 81: 445-452.
25. Vernet D et al. Differentiation phenotype of myofibroblasts from penile tuncia albuginea. J Urol 2001; 165: 200.
26. Bridge JA et al. Clonal chromosomal abnormalities in desmoid tumors. Implications for histopathogenesis. Cancer 1992; 69: 430-436.
27. Rudolph R, Vande Berg J. The myofibroblast in Dupuytren's contracture. Hand Clin N Am 1991; 7: 683-692.
28. Bowser-Riley S, Bain AD, Noble J, Lamb DW. Chromosome abnormalities in Dupuytren's disease. Lancet 1975; 2: 1282- 1283.
29. Mosmann T. Rapid calorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. JImmun Methods 1983; 65: 55-58.
30. El-Sakka A et al. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999; 161: 1980-1983.
31. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395-1399.
32. Wegner HE, Andersen R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol 1995; 28: 236-240.
33. Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000; 12 (Suppl 3): S25-31.
34. Cross SM et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267: 1353-1356.
35. Ioakim-Liossi A et al. p53 Protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology 2001; 12: 197-202.
36. Leite KR et al. Abnormal expression of mdm2 in prostate carcinoma. Mod Pathol 2001; 14: 428-436.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
38. Cordon-Cardo C et al. p53 Mutations in human bladder cancer genotypic versus phenotypic patterns. Int J Biochem Cell Biol 1994; 56: 347-350.
39. Campomenosi P et al. p53 Mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001; 20: 3573-3579.
40. Hoos A et al. Characterization of molecular abnormalities in human fibroblastic neoplasms: A model for genotype-phenotype association in soft tissue tumors. Cancer Res 2001; 61: 3171-3175.
41. Halberg RB et al. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci USA 2000; 97: 3461-3466.
42. Moffatt EJ, Kerns BJ, Madden JM, Layfield LJ. Prognostic factors for fibromatoses: A correlation of proliferation index, estrogen receptor, p53, retinoblastoma, and src gene products and clinical features with outcome. J Surg Oncol 1997; 65: 117-122.
43. Muller E et al. Molecular genetic and immunohistochemical analysis of the tumor suppressor genes Rb and p53 in palmar and aggressive fibromatosis. Diagn Mol Pathol 1996; 5: 194-200.
44. Mulhall JP, Branch J, Lubrano T, Shankey TV. Perturbations of cell cycle regulators in Peyronie's disease. Int J Impot Res 2001; 13(Suppl 5): S21-S28.